Skip to content
Catalyst

knowcompoundsO-acetyl-(R)-carnitine

Specimen compound organic compoundPlate I

O-acetyl-(R)-carnitine

An acetic acid ester of carnitine that facilitates movement of acetyl COA into the matrices of mammalian mitochondria during the oxidation of fatty acids.”

Nested hairline contours trace the electron density of one computed shape of O-acetyl-(R)-carnitine, teal at the edge warming to amber over the atoms.

432 readings, by contour and atom

fig. 1O-acetyl-(R)-carnitine · electron density · PubChem CID 7045767, computed 3D conformer
Formula
C9H17NO4
Molar mass
203.238 g/mol
PubChem CID
7045767
InChIKey
RDHQFKQIGNGIED-MRVPVSSYSA-N

– no difference found 4 findings in 4 endpoints

01 · the evidence, ordered

What the evidence says

Strong
0
Moderate
4
Limited
0
Very limited
0
Insufficient
0

How to read these marks

Fig. 2 O-acetyl-(R)-carnitine CHEBI:57589 4 endpoints 4 findings
×1.60
Labels
CompoundInspector

O-acetyl-(R)-carnitine

Most findings

  • HDL cholesterol×1
  • LDL cholesterol×1
  • Total cholesterol (TC)×1
  • Triglycerides×1

17 reference statements, not drawn · 36 compounds on the outer ring, not drawn

Keys

← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it

  1. HDL cholesterol
  2. LDL cholesterol
  3. Total cholesterol (TC)
  4. Triglycerides
fig. 3 · 4 endpoints · 4 findingsno endpoint contested

02 · findings

What O-acetyl-(R)-carnitine moved, and by how much

  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed
  1. TriglyceridesMoved: no difference foundEvidence: ModeratePaper: PMID 296962412018
    Who
    Adults over 40 with type 2 diabetes, hypertension and dyslipidemia, all on simvastatin 10 to 20 mg/d in both arms; ALC 116 and placebo 113 randomised; 6 months
    Dose studied
    acetyl-L-carnitine 1000 mg orally twice daily for 6 months

    The effect of ALC on triglycerides, lipoprotein(a), LDL, HDL, and total cholesterol was not significantly different from that of placebo.”

    Quoted verbatim from Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial.RCT · 6 monthsPermalink
  2. HDL cholesterolMoved: no difference foundEvidence: ModeratePaper: PMID 296962412018
    Who
    Adults over 40 with type 2 diabetes, hypertension and dyslipidemia, all on simvastatin 10 to 20 mg/d in both arms; ALC 116 and placebo 113 randomised; 6 months
    Dose studied
    acetyl-L-carnitine 1000 mg orally twice daily for 6 months

    The effect of ALC on triglycerides, lipoprotein(a), LDL, HDL, and total cholesterol was not significantly different from that of placebo.”

    Quoted verbatim from Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial.RCT · 6 monthsPermalink
  3. LDL cholesterolMoved: no difference foundEvidence: ModeratePaper: PMID 296962412018
    Who
    Adults over 40 with type 2 diabetes, hypertension and dyslipidemia, all on simvastatin 10 to 20 mg/d in both arms; ALC 116 and placebo 113 randomised; 6 months
    Dose studied
    acetyl-L-carnitine 1000 mg orally twice daily for 6 months

    The effect of ALC on triglycerides, lipoprotein(a), LDL, HDL, and total cholesterol was not significantly different from that of placebo.”

    Quoted verbatim from Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial.RCT · 6 monthsPermalink
  4. Total cholesterol (TC)Moved: no difference foundEvidence: ModeratePaper: PMID 296962412018
    Who
    Adults over 40 with type 2 diabetes, hypertension and dyslipidemia, all on simvastatin 10 to 20 mg/d in both arms; ALC 116 and placebo 113 randomised; 6 months
    Dose studied
    acetyl-L-carnitine 1000 mg orally twice daily for 6 months

    The effect of ALC on triglycerides, lipoprotein(a), LDL, HDL, and total cholesterol was not significantly different from that of placebo.”

    Quoted verbatim from Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial.RCT · 6 monthsPermalink

No dose is advised.

  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed

03 · identity

Structure

fig. 4O-acetyl-(R)-carnitine · 2D structure · ChEBI’s SMILES
fig. 5O-acetyl-(R)-carnitine · 3D conformer · PubChem CID 7045767, computed
Charge
0
SMILES
CC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C

04 · reach

What it touches on the way

7 entities · assembled from reference reactions

  1. CRATProtein81 paths · 57 endpointsinferred
  2. CPT1AProtein28 paths · 28 endpointsinferred
  3. SLC25A20Protein20 paths · 5 endpointsinferred
  4. SLC22A5Protein15 paths · 5 endpointsinferred
  5. CPT2Protein15 paths · 15 endpointsinferred
  6. CPT1BProtein8 paths · 8 endpointsinferred
  7. CPT1CProtein4 paths · 4 endpointsinferred

Where it reaches

17 regions · transporter routes

  1. Colon and rectumdigestive2 routesinferred
  2. Skeletal musclemusculoskeletal2 routesinferred
  3. Airway and sinusesrespiratory1 routeinferred
  4. Bladderurinary1 routeinferred
  5. Blood and immuneimmune1 routeinferred
  6. Brainnervous1 routeinferred
  7. Female reproductivereproductive1 routeinferred
  8. Gallbladderdigestive1 routeinferred
  9. Heartcardiovascular1 routeinferred
  10. Liverdigestive1 routeinferred
  11. Male reproductivereproductive1 routeinferred
  12. Mouth and oesophagusdigestive1 routeinferred
Show the remaining 5Show the first 12
  1. Pancreasendocrine1 routeinferred
  2. Skinintegumentary1 routeinferred
  3. Small intestinedigestive1 routeinferred
  4. Stomachdigestive1 routeinferred
  5. Thyroidendocrine1 routeinferred

05 · documented · reference

Interactions

Documented interactions
None reported

Pairs that share biology

What the reference databases state

Reference statements
1701 ProteinCRAT, SLC22A15, SLC22A5, SLC25A20, CPT1A, CPT1B, and 2 more02 Compound(R)-carnitineinferred, one hop from O-acetyl-(R)-carnitine
Reactions · Rhea
16reactions
17Reference statements

What the reference databases state

Evidence key

Statements

17 statements

Sources: Human-GEM, Rhea

97117 STATEMENTS
16Reactions

06 · on the label · 1,313 products

Labelled products

Source: NIH DSLD · Ingredient: O-acetyl-(R)-carnitine · 1,313 products · Declared amount per serving (the first 1,000 shown): 5–4,000 mg · 3 amounts above the serving weight, left out

749 labels of the first 1,000 shown state an amount251 do not

  • 'Merica LabzUncle BAM500 mgper 2 capsulesDSLD:200684
  • 1st Phorm1-Db Goddess200 mgper 2 capsulesDSLD:276835
  • 1st Phorm1-Db Overdrive200 mgper 2 capsulesDSLD:288071
  • 1st PhormThyro-Drive400 mgper 2 capsulesDSLD:276836
  • 4 OrganicsJumpstart Boost Formula EX10 mgper 1 capsuleDSLD:268152
  • 4 OrganicsJumpstart Boost Formula EX10 mgper 1 capsuleDSLD:268153
  • 4LifeRenuvoAcetyl-L-Carnitine HClamount not statedper 2 capsulesDSLD:301054
  • Absorb HealthAcetyl L-Carnitine 500 mg500 mgper 1 capsuleDSLD:215997
  • Activate SupplementsWave Blueberry Lemonade2 gper 10.95 gDSLD:320871
  • Adaptogen ResearchATP Natural Citrus FlavorAcetyl-L-Carnitine Hydrochlorideamount not statedper 7.9 gDSLD:307146
  • AddrenaNootropic Stimulant50 mgper 1 tabletDSLD:206821
  • AddrenaNootrostimAcetyl-L-Carnitine, as Acetyl-L-Carnitine HCl100 mgper 1 capsuleDSLD:206845
Show the remaining 1,301Show the first 12

Label record: NIH Office of Dietary Supplements · CC0

07 · the record

Sources

103

papers screened for O-acetyl-(R)-carnitine

admitted
1
read and discarded
73
not read yet
29

The screening record, every paper and why

Sources cited

1 paper · 4 findings

Show every paper citedHide the papers cited

Other names · 11

(-)-Acetylcarnitine · (3R)-3-acetyloxy-4-(trimethylazaniumyl)butanoate · (R)-Acetylcarnitine · Acetyl-L-(-)-carnitine · Acetyl-L-carnitine · CAR 2:0 · L-Acetylcarnitine · L-Carnitine acetyl ester · L-O-Acetylcarnitine · R-Acetylcarnitine

systematic · (3R)-3-(acetyloxy)-4-(trimethylazaniumyl)butanoate